Please assess the completion status of the following clinical trial:

Trial Title: Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Therapy-naive patients with histologically confirmed diagnosis of a locally inoperable or metastasized well-differentiated neuroendocrine tumor of the midgut~* curative surgery impossible~* two-dimensional tumor formation assessable by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)~* Age ≥ 18~* Karnofsky-index \> 60~* written informed consent~* proliferation index for Ki67~Exclusion Criteria:~* hypersensitivity to octreotide~* poorly differentiated or small cell neuroendocrine tumors~* primary tumor outside of the midgut~* prior treatment with somatostatin-analogue \> 4 weeks~* prior treatment with alpha-interferon, chemotherapy, or chemoembolisation~* participation in any other clinical trial~* pregnancy or lactation~* no secondary malignancy in anamnesis; with the exception of patients without any manifestation of the secondary malignancy (without relapse) after curative therapy within the last five years~* severe decompensated organ malfunction (heart-, liver- insufficiency)~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octreotide LAR (Long Acting Release) (Type: EXPERIMENTAL): Octreotide LAR 30 mg intramuscularly every 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - Sodium chloride intramuscularly every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).